Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Survodutide, a novel glucagon/GLP-1 dual agonist, proved cardiovascularly safe in a large phase 3 trial. The SYNCHRONIZE-CVOT trial showed the drug was noninferior to placebo for major adverse cardiovascular events in over 5,500 high-risk patients with obesity. It also delivered meaningful cardiometabolic improvements — but experts caution it hasn't proven it can reduce CV risk.
Survodutide, an investigational glucagon/GLP-1 receptor dual agonist from Boehringer Ingelheim, has cleared a key hurdle: cardiovascular safety. In the global, phase 3 SYNCHRONIZE-CVOT trial — presented at the American Heart Association annual meeting and published simultaneously in The Lancet — survodutide was noninferior to placebo for a five-point MACE composite endpoint in more than 5,500 adults with obesity and established or high-risk cardiovascular disease or chronic kidney disease.
Beyond safety, the drug also showed meaningful cardiometabolic benefits, including reductions in systolic blood pressure, waist circumference, HbA1c, body weight, lipid levels, and high-sensitivity C-reactive protein. Gastrointestinal side effects were common, particularly during dose escalation, with GI-related discontinuation rates of ~19–21% in the treated groups versus ~2% with placebo.
By the Numbers
Why it matters: Establishing CV safety is a regulatory prerequisite for new obesity drugs, and survodutide passes that test. However, experts note that noninferiority is a relatively low bar — other agents in the class have already demonstrated CV superiority. Clinicians will need to weigh survodutide's cardiometabolic benefits against its tolerability profile and the availability of drugs with proven CV outcome benefits when making prescribing decisions.
